|Bid||334.75 x 0|
|Ask||540.00 x 0|
|Day's Range||363.15 - 363.15|
|52 Week Range||258.50 - 368.25|
|PE Ratio (TTM)||103.17|
|Forward Dividend & Yield||4.43 (1.32%)|
|1y Target Est||N/A|
Vasant Narasimhan, the 41-year-old chief executive at Novartis AG, is vowing data science and digital technologies will revolutionize the company’s drug-development pipeline.
As the battle to buy Pfizer’s $20 billion consumer business heats up, Lysol-owner Reckitt Benckiser is trying to convince investors that its acquisition record is clean.
If there were a healthcare Olympics, this company would bring home the gold this year for its dividend-friendly performance.
Pfizer Inc (NYSE:PFE) outperformed the Pharmaceuticals industry on the basis of its ROE – producing a higher 34.94% relative to the peer average of 10.62% over the past 12 months.Read More...
Alberta Investment Management Corp. invests on behalf of 26 provincial pension, endowment and government funds, but that might not be obvious to an observer based on the pension manager’s fourth-quarter trades. Aimco, as the entity is known, made some drastic changes in the overall portfolio, trades that we’d expect to see in an aggressively managed fund on the hunt for growth, not in what we’d assume should be an approach as focused on protection as incremental upside. Perhaps the funds Aimco manages are incentivized to find big, immediate returns.
Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. PFE credit default swap spreads are within the middle of their range for the last three years.
FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.
Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies. In the late stage trial of Bavencio, the drug could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.
FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. The ...
DARMSTADT, Germany and NEW YORK , February 15, 2018 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing ...
Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.
Pfizer Inc. today announced its once-daily oral Janus kinase 1 inhibitor PF-04965842 received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the treatment of patients with moderate-to-severe atopic dermatitis .
Pimco is the largest bond investor, but it also manages quite a bit in equities. According to S&P Capital IQ, Pimco now oversees $5.1 billion in U.S. equities. While U.S. stocks were “a little expensive,” Ivascyn said Pimco has “a mild preference for financials, housing-related investments, and investments tied to the consumer.” The appetite for consumer-tied stocks hadn’t abated by the fourth quarter, when Pimco increased its investment in Apple (AAPL) more than tenfold.
Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer's drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease. The company was testing the drug, Verubecestat, in patients with very early, or prodromal, Alzheimer's disease. It scrapped the study almost exactly one year after ending a different late-stage trial of the same drug in patients with mild to moderate Alzheimer's disease.
The reasons Pfizer recently decided to stop pursuing neurological disease research and what to look forward to in the near future regarding Alzheimer's disease treatments
Pfizer's (PFE) regulatory applications seeking approval for tyrosine kinase inhibitor, lorlatininb, for treating second or later line NSCLC accepted in the United States, Europe and Japan.
Novartis's (NOVN.S) Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per millilitre injection of the Novartis copy of Copaxone, Teva's (TEVA.N)(TEVA.TA) blockbuster medicine, Sandoz said in a statement on Tuesday. Israel-based Teva Pharmaceutical Industries began facing competition for its 40 mg version of Copaxone from Mylan (MYL.O) in October and has been bracing for more copycat versions of its bestselling drug.
Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per millilitre injection of the Novartis copy of Copaxone, Teva's blockbuster medicine, Sandoz said in a statement on Tuesday. Israel-based Teva Pharmaceutical Industries began facing competition for its 40 mg version of Copaxone from Mylan in October and has been bracing for more copycat versions of its bestselling drug.
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / Shares of Teva came back swinging in Monday trading after seeing losses last week after a disappointing quarterly report. Credit Suisse deciding to upgrade ...